-

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences:

  • Stephens Investment Conference in Nashville, TN. Fireside chat on Wednesday, November 19, 2025, at 8am CT.
  • Piper Sandler Healthcare Conference in New York, NY. Presentation on Wednesday, December 3, 2025, at 4:30pm ET.

Live and archived webcasts of the presentations will be available on the “Events and Presentations” section of the CareDx investor relations website at investors.caredx.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit www.caredx.com.

Contacts

Investor Relations
Caroline Corner
investor@caredx.com

Industry:

CareDx, Inc.

NASDAQ:CDNA
Release Versions
English

Contacts

Investor Relations
Caroline Corner
investor@caredx.com

More News From CareDx, Inc.

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world...

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On February 24, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an agg...

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company’s Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company’s finance organization effective...
Back to Newsroom